Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Leiomyoma × Aromatase Inhibitors × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 55 Polycystic Ovary Syndrome 3 Neoplasms, Hormone-Dependent 3 Neoplasm Metastasis 2 Carcinoma, Lobular 2 Carcinoma, Intraductal, Noninfiltrating 2 Carcinoma, Ductal, Breast 2 Breast Cancer Female 2 Advanced Breast Cancer 2 Sexuality 1 Osteoporosis 1 Luminal B/HER2-negative Breast Cancer 1 Leiomyoma 1 Infertility 1 Hormone Receptor Positive Breast Carcinoma 1 Hormonal Receptors Positive, HER2 Negative, Advanced Breast Cancer 1 Fractures, Bone 1 Estrogen Receptor and/or Progesterone Receptor Positive 1 Endometrial Neoplasms 1 Bulbo-Spinal Atrophy, X-Linked 1 Breast Neoplasms, Male 1 Breast Diseases 1 Breast Carcinoma In Situ 1 Breast Cancer Metastatic 1 Bone Diseases, Metabolic 1 Arthralgia 1 Anatomic Stage I Breast Cancer AJCC v8 1

Interventions

ulipristal acetate 16 telapristone acetate 16 Uterine Myomectomy 12 vilaprisan 11 Leuprolide 9 asoprisnil 7 Uterine Artery Embolization 7 Mifepristone 7 ulipristal 6 relugolix 6 estradiol, norethindrone drug combination 6 elagolix 6 Tranexamic Acid 6 Bupivacaine 6 Estradiol 5 linzagolix 4 epigallocatechin gallate 4 Sodium Chloride 4 Saline Solution 4 Norethindrone Acetate 4 Letrozole 4 Hysterectomy 4 Vitamin B 6 3 Misoprostol 3 Gonadotropin-Releasing Hormone 3 Embolization, Therapeutic 3 cetrorelix 2 Vitamin D 2 Tea 2 Sugars 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00945360 2012-07-13

Aromatase Inhibitors for Treatment of Uterine Leiomyomas

American University of Beirut Medical Center

Phase 1 Withdrawn

Leiomyoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡